Saracatinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Saracatinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Saracatinib can convert its Small molecule drug profile and FYN biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Saracatinib (query alias: Saracatinib) |
|---|---|
| Modality / target | Small molecule drug; FYN; FYN inhibitors |
| Highest global status | Phase 2 |
| Originator | AstraZeneca PLC |
| Active developers | AstraZeneca PLC, AstraZeneca Pharmaceuticals Co. Ltd., National Institutes of Health |
The MCP disease footprint includes Myositis Ossificans, Alzheimer Disease, Idiopathic Pulmonary Fibrosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04307953 | Phase 2 | Active, not recruiting | 20 | Primary endpoint not disclosed in English source |
| NCT03661125 | Early Phase 1 | Unknown status | 30 | Primary endpoint not disclosed in English source |
| NCT02955186 | Phase 2 | Completed | 50 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Phase 2; n=140; evaluation: Negative. Reported fields: PFS = 3.7 Month ; PFS = 5.6 Month
SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.
Phase 1/2; n=not disclosed; evaluation: Negative. Reported fields: PFS: HR = 1.35(80% CI, 1.07 - 1.7); PFS: HR = 1.35(80% CI, 1.07 - 1.7)
Fyn Kinase Inhibitors and Alcohol Drinking
Phase 2; n=50; evaluation: Not stated in English source. Reported fields: Change in the Number of Drinks Consumed From Baseline to Day 8 (Minus Baseline)(LS Mean) = -1.85 drinks ; Change in the Number of Drinks Consumed From Baseline to Day 8 (Minus Baseline)(LS Mean) = -2.33 drinks
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Saracatinib addresses Myositis Ossificans, Alzheimer Disease, Idiopathic Pulmonary Fibrosis. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 6 matched transaction record(s) under the scope “target-level comparable: FYN.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: FYN records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-10-16 | Onco360 to distribute Cycle Pharmaceuticals' PHYRAGO against acute lymphoblastic leukemia and chronic myeloid leukemia in the US | Approved | Financial terms not disclosed |
| 2025-08-12 | Xspray Pharma Signs License Agreement with Handa Therapeutics – to Receive up to Double-Digit Royalty on Handa’s Net Proceeds | Approved | Financial terms not disclosed |
| 2025-07-21 | Cycle Pharmaceuticals Signs Exclusive U.S. Sales License for PHYRAGO™ (dasatinib) Tablets | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Application of SRC inhibitor in preparation of acute pancreatitis medicine”. The milestone feed surfaced a patent-application signal described as “Ilicin A-based blank liposome, drug-loaded liposome, and preparation method and application of ilicin A-based blank liposome and drug-loaded liposome”. The milestone feed surfaced a patent-application signal described as “ICAM-1 targeted car constructs and methods of treatment”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
